The Board of Directors of Milestone Medical (WAR:MMD, the Company, the Issuer) today announced that Milestone Scientific, licensor of the Company’s computer-controlled injection and drug delivery technology, has commenced trading of its common shares on the NYSE MKT, which is subject to continued satisfaction of listing requirements. Milestone Scientific continues to trade under the symbol “MLSS.”
The listing of Milestone Scientific’s common shares on the NYSE MKT illustrates both the commercial progress and reception to the core technology in the U.S. capital markets. With Milestone Scientific owning 49.9% of the Issuer, its listing on the NYSE MKT should provide both Milestone Scientific and the Company with increased exposure within the investment community. This move aligns with the Company’s own plans to uplist from the NewConnect market to Main Market of Warsaw Stock Exchange this year.
NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE’s advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.
Legal basis: Section 3.1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”.
Osoby reprezentujące spółkę:
Joseph D'Agostino - CFO